

### Supplemental Digital Content 3 – Excluded studies

We excluded six articles because of uncertainty whether they shared patients with other publications: Alexander *et al.* 2000 [1] and Varghese *et al.* 2010 [2] (excluded) with Alexander *et al.* 2003 [3]; Ben-Shabat *et al.* 2017 [4] and Olofsson *et al.* 2014 [5] (excluded) with Ben-Shabat *et al.* 2016 [6]; Gonsalves *et al.* 2011 [7] (excluded) with Eldredge-Hindy *et al.* 2014 [8]; and Noter *et al.* 2004 [9] (excluded) with de Leede *et al.* 2016 [10]. We tabulate Kodjikian *et al.* 2005 [11] and Rivoire *et al.* 2005 [12] together as they apparently overlap completely.

In one article, a “nonsurgery” subgroup of 86 patients could not be assigned to specific modality [13]. A subgroup with combination chemotherapies in the article by Pons *et al.* was included in the pooled conventional chemotherapy (CHT) group but could not be analysed by agent, and six surgically treated patients did not have individual survival times [14].

### References

- 1 Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. *Clin Cancer Res* 2000; **6**:3062-3070.
- 2 Varghese S, Xu H, Bartlett D, Hughes M, Pingpank JF, Beresnev T, *et al.* Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. *Ann Surg Oncol* 2010; **17**:1870-1877.
- 3 Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, *et al.* Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. *Clin Cancer Res* 2003; **9**:6343-6349.
- 4 Ben-Shabat I, Belgrano V, Hansson C, Olofsson Bagge R. The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases. *Int J Hyperthermia* 2017:1-17.
- 5 Olofsson R, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, *et al.* Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. *Ann Surg Oncol* 2014; **21**:466-472.
- 6 Ben-Shabat I, Belgrano V, Ny L, Nilsson J, Lindnér P, Olofsson Bagge R. Long-term follow-up evaluation of 68 patients with uveal melanoma liver metastases treated with isolated hepatic perfusion. *Ann Surg Oncol* 2016; **23**:1327-1334.
- 7 Gonsalves CF, Eschelmann DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. *American journal of roentgenology* 2011; **196**:468-473.
- 8 Eldredge-Hindy H, Ohri N, Anne PR, Eschelmann D, Gonsalves C, Intenzo C, *et al.* Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. *Am J Clin Oncol* 2016; **39**:189-195.
- 9 Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, *et al.* Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. *Melanoma Res* 2004; **14**:67-72.
- 10 de Leede EM, Burgmans MC, Kapiteijn E, Luyten GP, Jager MJ, Tijl FG, *et al.* Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres. *Melanoma Res* 2016; **26**:588-594.
- 11 Kodjikian L, Grange JD, Baldo S, Baillif S, Garweg JG, Rivoire M. Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. *Graefes Arch Clin Exp Ophthalmol* 2005; **243**:622-624.
- 12 Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Négrier S, Grange JD. Treatment of liver metastases from uveal melanoma. *Ann Surg Oncol* 2005; **12**:422-428.
- 13 Hsueh EC, Essner R, Foshag LJ, Ye X, Wang HJ, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. *Cancer* 2004; **100**:122-129.
- 14 Pons F, Plana M, Caminal JM, Pera J, Fernandes I, Perez J, *et al.* Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients. *Melanoma Res* 2011; **21**:217-222.